Kornimate/medical-research-clean huggingface dataset:
a study evaluating clarivein with a sclerosing agent for the treatment of venous insufficiency

Conditions: Venous Insufficiency

Summary: vicares is a prospective randomized, controlled, multi-center, double blind study treating venous insufficiency associated with incompetent saphenous veins with 1% and 3% sodium tetradecyl sulfate (sts) solution utilizing the clarivein system.

approximately 50 subjects diagnosed with an incompetent saphenous vein will be randomized to either 1% sts or 3% sts solution delivered by the clarivein system under ultrasound guidance. study duration for individual study patients, including follow-up visits, is anticipated to be approximately 16 weeks.

Eligibility criteria:
inclusion criteria: 1. adult patient with incompetent saphenous vein 2. saphenous vein reflux \> 500ms (0.5s), as measured by duplex ultrasound 3. one or more of patient reported symptoms related to the target vein: i.e., heaviness, achiness, swelling, throbbing or itching. 4. candidate for endovenous procedure exclusion criteria: 1. arterial insufficiency demonstrated by a history of peripheral arterial disease (pad) that would preclude the wearing of compression stockings 2. absence of a palpable pulse at posterior tibial or dorsalis pedis and an ankle-brachial index (abi) \<0.6 3. multi-segmental axial deep venous reflux in at least two contiguous venous segments (e.g., femoral and popliteal) in the ipsilateral extremity 4. previous surgical or endovenous procedure in the treatment section of the target vein 5. previous superficial thrombophlebitis of the target saphenous vein with scarring in the treatment section 6. pregnant or breastfeeding 7. known sensitivity or allergic response to sodium tetradecyl sulfate (sts) 8. known high risk of thrombosis 9. known history of deep vein thrombus (dvt) or pulmonary embolism (pe), known history of acute superficial vein thrombus, known hypercoagulable condition, post thrombotic syndrome 10. known history of anaphylaxis or presence of multiple severe allergies
the clinical utility of quantiferon in the diagnosis of active tuberculosis

Conditions: Tuberculosis

Summary: the investigators will evaluate the usefulness of quantiferon-tb gold in-tube (qft) in the diagnosis of active tuberculosis in young adults group, highly clinically suspected tuberculosis.

investigators will enroll prospectively all clinically and radiologically suspected tuberculosis patients from 20 to 29 years old who visited the armed forces capital hospital. investigators will perform qft and tuberculin skin test. diagnosis of tuberculosis will be made by world health organization guideline and the physician will not know the quantiferon-tb gold in-tube results before the diagnosis and anti-tuberculosis medication. investigators will evaluate the sensitivity and specificity of quantiferon-tb gold in-tube in the diagnosis of active tuberculosis among young adults.

Eligibility criteria:
inclusion criteria: * all clinically and radiologically suspected tb patients from 20 to 29 years old who visited the armed forces capital hospital exclusion criteria: * soldiers who do not agree with study protocol

Keywords: tuberculosis pneumonia quantiferon-tb gold in-tube tuberculin skin test
effects of proxelan somministration in patients with chronic prostatitis

Conditions: Chronic Prostatitis; Chronic Prostatitis With Chronic Pelvic Pain Syndrome; Premature Ejaculation

Summary: the purpose of the study is to determinate the antinflammatory effects of the proxelan on a cohort of patients affected by prostatitis'like symptoms and clinical evidence of abacterical prostatistis, trough a significative improvements of pain symptoms according to the nih-cpsi questionnaire items, spermatozoa motility/concentration variations and the semen cytokines level decrease.


Eligibility criteria:
inclusion criteria: - prostatitis like symptoms for at least three months exclusion criteria: * significant post-voidal residual volume * meares and stamey test suggestive for bacterial infection * neoplasms, * urinary stones, * antibiotic therapy in the previous three months, * irritable bowel syndrome, * previous radiotherapic or chemiotherapic treatment, * urethral stenosis, * neurogenic bladder * previous prostatic surgery

Keywords: prostate inflammation cps/cpps prostatitis proxelan
intra-venous acetaminophen and muscle relaxants after total knee

Conditions: Unilateral Knee Arthroplasty

Summary: this is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores.

this research will be a prospective, three-arm, randomized, open-label trial to assess opioid use and patient reported outcomes after 48 hours of regular iv acetaminophen and muscle relaxant (ivam) orphenadrine administration following total knee replacement surgery. 180 patients (60 in each arm) will be randomized to receive the standard group treatment, the ivam group treatment, or to the control grouptreatment. standard group treatment: includes peripheral nerve single injection or catheter infusions (48 hours) as requested by the surgeon; preoperative (single dose) intravenous acetaminophen (1000 mg) and orphenadrine (60 mg); intraoperative spinal anesthesia or general anesthesia as determined by the anesthesia attending physician; postoperative oral oxycodone (5 mg) with acetaminophen (325 mg) (prn dosing), oral orphenadrine (100 mg) every 12 hours for 3 doses, and intravenous hydromorphone (prn dosing) for breakthrough pain. control group treatment: includes peripheral nerve single injection or catheter infusions (48 hours); preoperative (single dose) intravenous acetaminophen (1000 mg) intraoperative spinal anesthesia or general anesthesia as determined by the anesthesia attending physician; and postoperative oral oxycodone and acetaminophen (prn dosing), and intravenous hydromorphone (prn dosing) for breakthrough pain. ivam group treatment: includes peripheral nerve single injection or catheter infusions (48 hours); preoperative intravenous acetaminophen (1000 mg) and orphenadrine (60 mg); intraoperative spinal anesthesia or general anesthesia as determined by the anesthesia attending physician; postoperative intravenous acetaminophen (1000 mg) every 6 hours routine for total of 8 doses and intravenous orphenadrine (60 mg) every 12 hours for total of 4 doses; oral oxycodone (5 mg) (prn dosing), and intravenous hydromorphone (prn dosing) for breakthrough pain.

Eligibility criteria:
inclusion criteria: 1. age 18-85 2. primary, unilateral total knee arthroplasty 3. american society of anesthesiologist (asa) physical status i, ii, or iii exclusion criteria: 1. chronic pain (as determined by regular opioid use in the month preceding surgery) 2. preoperative use of centrally acting muscle relaxants in the 24 hours preceding surgery 3. peripheral regional anesthesia procedures other than femoral nerve injections or catheters for postoperative pain control (such as popliteal block) 4. severe renal dysfunction, creatinine \> 2.0 5. allergy or other contraindications to use of orphenadrine and/or acetaminophen 6. pregnant or breast feeding 7. abnormal liver function tests(lft) and / or history of chronic/excessive alcohol abuse. 8. history of hepatitis, b or c, 9. history of cirrhosis or hepatic insufficiency
special survey of production of insulin aspart specific antibody

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in japan. the aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.


Eligibility criteria:
inclusion criteria: * patients with diabetes requiring insulin therapy exclusion criteria: * patients who had a treatment history of novorapid® (insulin aspart)
nurse-led educational intervention on heart failure patients

Conditions: Heart Failure

Summary: a randomized controlled study to examine the effect of a nurse-led, home/telephone or telephone-only educational intervention on outcomes of heart failure patients and their caregivers.


Eligibility criteria:
inclusion criteria: * written informed consent * men or women aged ≥18 years old. * hospitalized for new-onset or decompensated chronic heart failure. exclusion criteria: * any severe neuromuscular disease or other disability or mobility problems that preclude performance of six-minute walk test. * any severe cognitive dysfunction or psychiatric disease that limit ability to receive education. * patients unable to be contacted by phone or other means.

Keywords: heart failure management programmes nurse-led educational interventions self-care health-related quality of life caregiver outcomes
genentech xenon mri idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the purpose of this study is being done to determine whether magnetic resonance imaging (mri) using inhaled hyper-polarized 129 xenon gas can help visualize impaired lung function to detect changes over time in idiopathic pulmonary fibrosis (ipf) patients receiving approved ipf treatments. subjects will undergo an approximately hour long comprehensive mri protocol, including administration of multiple doses of hyper-polarized 129 xenon. the subjects will have this initial study prior to initiation of ipf therapies. then the subjects will have repeat studies at 3, 6 and 12 months following the initiation of therapy. additional studies including pulmonary function studies, serum for bio markers, 6 minute walk distance and a high-resolution computed tomography (hrct) scan (only at the 6 month visit) will be performed to determine how 129 xenon mri performs relative to standard of care evaluations for ipf. the mri uses a magnet and radio waves to make diagnostic medical images of the body. there have been no ill effects reported from exposure to the magnetism or radio waves used in this test. risks of the xenon gas are slight numbness in legs, nausea, a feeling of well-being, and mild tingling in fingertips. you will have pulmonary function testing for the study, you may experience breathlessness or dizziness during or immediately following these tests.


Eligibility criteria:
inclusion criteria: * outpatients of either gender, age \> 18. * willing and able to give informed consent and adhere to visit/protocol schedules. (consent must be given before any study procedures are performed) * clinical diagnosis of ipf by confirmed by multidisciplinary diagnosis and naïve to treatment with an approved ipf therapy (either nintedanib or pirfenidone) exclusion criteria: * subject is less than 18 years old * subjects who have been previously on either pirfenidone or nintedanib * mri is contraindicated based on responses to mri screening questionnaire * subject is pregnant or lactating * resting oxygen saturation on room air \<90% on supplemental oxygen * respiratory illness of a bacterial or viral etiology within 30 days of mri * subject with ventricular cardiac arrhythmia in the past 30 days. * subject has history of cardiac arrest within the last year * subject does not fit into 129 xenon vest coil used for mri * subject deemed unlikely to be able to comply with instructions during imaging * recent exacerbation (within 30 days) defined by the need for antibiotics and/or systemic steroids * medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
infant tb infection prevention study

Conditions: Tuberculosis

Summary: randomized controlled trial (rct) of isoniazid (inh) vs. no inh to prevent mycobacterium tuberculosis infection in hiv-exposed uninfected (heu) infants.

the purpose of this trial is to determine whether isoniazid (inh) reduces the risk of mycobacterium tuberculosis (mtb) infection in hiv-exposed but uninfected (heu) children, as well as to determine epidemiologic and immunologic correlates of mtb infection in heu.

Eligibility criteria:
inclusion criteria: * hiv exposed infants * aged 6 weeks within (+ 4 weeks) * born to hiv-infected mothers * not premature and over 2.5 kg exclusion criteria: * infants with known exposure to active tb in household * premature and \< 2.5 kg

Keywords: m. tuberculosis infection isoniazid hiv-exposed infants
acute effects of a passive stretching session on the mechanical properties of medial gastrocnemius muscle in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: children with cerebral palsy present early in the childhood altered muscular properties, as soon as structural or stiffness. in the gastrocnemius muscle, altered muscular properties are characterized by short muscle belly length and increased stiffness which contribute to contracture and limiting joint range of motion. this study assess efficacy of an acute high intensity and long-time stretching session of plantarflexors muscle on their viscoelasticity properties and maximal dorsiflexion angle gain. single stretching session is characterized by high intensity and long time (5 minutes).


Eligibility criteria:
inclusion criteria: * children with cerebral palsy of the spastic type * children with a maximum dorsal ankle flexion amplitude limitation of less than 10°. exclusion criteria: * children who have undergone surgery on the lower limbs. * children with a botulinum toxin injection and/or a series of elongation casts for less than three months. * children with ongoing analgesic treatment

Keywords: children medial gastrocnemius muscle
perception and knowledge about menopause among pakistani woman

Conditions: Menopause

Summary: this study is conducted to find out perception and knowledge about menopause among pakistani woman.

the survey for was conducted in various location and clinics all over pakistan. 1200 numbers of questionnaires were distributed of which 910 numbers responded from 1st january 2018 to 28th february 2018. those who agreed to be part of study where ask a self-structured questionnaire related to awareness and symptoms of menopause. data was analyzed using spss version 23.0. frequencies were calculated for categorical data.

Eligibility criteria:
inclusion criteria: * female aged 35 to 55 * oral informed consent exclusion criteria: * none
cleveland african american prostate cancer project

Conditions: Prostate Cancer

Summary: the purpose of this research is to test intervention strategies that encourage and support black or african american men who are 40 and older to complete prostate cancer screening, and specifically to complete a prostate-specific antigen (psa) test.

this intervention is designed to evaluate the effectiveness of three different approaches to increasing psa screening in african american men, starting at age 40. the approaches are 1) education and passive navigation, 2) education and active navigation, and 3) education and active navigation with community based outreach. completion of a psa blood test is the primary outcome of this study, which will be evaluated four months following the recruitment phase at each shop. at the 4 month follow-up, participants will be asked about psa completion; participants who completed psa screening will be asked to provide outcomes from their psa screening (ie. psa results and provider recommended next steps), as well as their feelings regarding their screening experience, trust in the screening process, and knowledge about prostate cancer.

Eligibility criteria:
inclusion criteria: * ≥40 years old * self-identify as black or african american * have a prostate gland (includes biological males, transwomen) * psa-naïve or has not received a psa test in the past 12 months * has not had a previous prostate cancer diagnosis * english speaking * ability to consent to study exclusion criteria: * individuals who have had a prostatectomy
a complicated skin and soft-tissue infection patient registry

Conditions: Staphylococcal Skin Infections; Diabetic Foot Infections; Surgical Wound Infection; Abscess; Cellulitis

Summary: the purpose of this registry is to better understand (1) complicated skin and soft-tissue infections requiring hospitalization, and (2) clinical and economic outcomes in hospitalized patients receiving intravenous antibiotic therapy.

a prospective, multi-center, observational study involving 1200 patients hospitalized for the treatment of csstis. the study will be conducted at approximately 50 hospitals in the us. patients who consent to participate in the registry will be enrolled in the registry within 24 hours of initial iv antibiotic therapy for treatment of one or more cssti types. sites will treat patients according to their usual clinical practice. the objective of this registry is to characterize csstis with respect to patient characteristics and describe patient outcomes.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of complicated skin and soft-tissue infection * patients who require iv antibiotic therapy as a primary treatment regimen * patients who are deemed to be cognitive and able to provide written informed consent and follow-up information. exclusion criteria: * patients with a diagnosis at the index infection site of necrotizing soft tissue infection, burn, gangrene, decubitus ulcer, animal or human bites, known or suspected osteomyelitis, or mediastinitis * patients for whom amputation or a complete resection of the infection site is a planned component of treatment * patients who are pregnant * patients simultaneously participating in any interventional clinical trial * patients with any other known or suspected condition that may jeopardize adherence to registry protocol requirements * patients who are employees of the investigator or study hospital

Keywords: complicated skin and soft-tissue infection skin infection skin infection registry cssti registry
adverse outcome of acute pulmonary embolism by artificial intelligence system based on ct pulmonary angiography

Conditions: Pulmonary Embolism and Thrombosis; Deterioration, Clinical; Artificial Intelligence

Summary: the investigators aim to build a predictive tool for adverse outcome of acute pulmonary embolism by artificial intelligence system based on ct pulmonary angiography.

this study collected clinical, laboratory, and ct parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital. the investigators aim to build a predictive tool for adverse outcome of acute pulmonary embolism by artificial intelligence system based on ct pulmonary angiography. eligible patients were randomized in some ratio into derivation and validation cohorts. the derivation cohort was used to develop and evaluate a multivariable logistic regression model for predicting the outcomes of interest. the discriminatory power was evaluated by comparing the nomogram to the established risk stratification systems. the consistency of the nomogram was evaluated using the validation cohort.

Eligibility criteria:
inclusion criteria: * age of ≥ 18 years and a pulmonary embolism diagnosis based on ct pulmonary angiography exclusion criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding ct parameters, echocardiography, cardiac troponin i (c-tn i), and n-terminal-pro brain natriuretic peptide (nt-pro bnp) levels.

Keywords: pulmonary embolism and thrombosis deterioration, clinical artificial intelligence
women's responses to a mindfulness-based body scan: a pilot study

Conditions: Post Traumatic Stress Disorder; Trauma, Psychological

Summary: ptsd develops after trauma and is marked by intrusive memories, avoidance of reminders, negative changes in mood and cognitive processes, and dysregulated physical and emotional stress reactivity. ptsd disparately affects twice as many women as men (8.0% vs. 4.1%), and finding effective treatments for these women is critical to reduce poor health outcomes associated with ptsd. mind-body therapies (mbt), using the mind in combination with the body to facilitate healing hold promise to enhance ptsd treatment by improving stress regulation. while mbt reduce ptsd symptoms long-term, women with ptsd may initially experience distress, leading to treatment avoidance. this pilot study will explore women's initial responses to mbt, the prevalence of adverse responses, and which women are at risk for adverse responses in a sample of participants with a history of trauma and varying levels of ptsd symptoms. study participants will attend one virtual study visit via one-on-one videoconference with the pi, where they will complete self-report measures of stress and affect before and after one session of a mbt exercise. a subset of the sample will complete a semi-structured individual videoconference interview with the pi within two weeks following completion of the mbt exercise and quantitative measures.

the proposed single-group study will use a pre-post design to assess participants' responses to one exposure to a mindfulness-based body scan in a sample of women with a history of trauma and varying levels of ptsd symptoms. quantitative measures will assess self-reported state positive affect, negative affect, and anxiety before and after the body scan, and psychosocial characteristics expected to influence responses. individual semi-structured interviews will be conducted with a subsample of women to learn about their subjective experiences related to the body scan.

Eligibility criteria:
inclusion criteria: 1. previously experienced a traumatic event as defined by the diagnostic and statistical manual of mental disorders (dsm-5) \>6 months prior, 2. self-identify as a woman and were assigned female sex at birth, 3. \>18 years of age, 4. fluency in english, 5. access to computer or smartphone to complete redcap surveys and videoconference study visit. exclusion criteria: 1. active suicidal thoughts with a plan, 2. unable to abstain from drugs or alcohol for \>48 hours prior to study videoconference, 3. current or history of psychosis with auditory and/or visual hallucinations, 4. meditated or practiced yoga \>1 time(s) per month over past 6 months.